{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:19:06Z","timestamp":1777792746773,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K12238, 21KK0156, 22K16679"],"award-info":[{"award-number":["24K12238, 21KK0156, 22K16679"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Brain stem gliomas harboring IDH mutations can be sensitive to temozolomide (TMZ) treatment, unlike their H3K27-altered counterparts, so distinguishing the two is essential.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Here, we report an adult brainstem glioma patient whose hearing loss normalized after treatment. He presented with gradual left hearing loss from two years before, and magnetic resonance (MR) images showed a diffuse mass lesion involving the pons to left middle cerebral peduncle, including the vestibular and cochlear nuclei. On MR spectroscopy (MRS), 2-hydroxyglutarate (2HG) was elevated to 3.602 mM, suggesting an IDH-mutant glioma. Subsequently, an open biopsy was performed via the lateral suboccipital approach, and the pathological diagnosis was astrocytoma, IDH-mutant, CNS WHO grade 3. Molecular analysis revealed a non-canonical <jats:italic>IDH2<\/jats:italic> R172S mutation. Left hearing improved from 87.5 dB to 8.3dB by 6-frequency pure tone audiogram (PTA) and 90% speech discrimination at 35 dB after concomitant TMZ and radiation treatment, followed by 12 cycles of adjuvant TMZ treatment. 2HG also decreased to 0.186 mM on MRS after treatment determining treatment strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Studies have shown that as high as 31% of adult brainstem gliomas are IDH mutant, with most of these mutations being non-canonical <jats:italic>IDH1\/2<\/jats:italic> mutations. Approximately 70% of IDH-mutant astrocytomas are known to harbor a methylated O6-methylguanine-DNA-methyltransferase (<jats:italic>MGMT<\/jats:italic>) promoter and respond to TMZ treatment, whereas almost all H3K27M-mutant diffuse midline gliomas have unmethylated <jats:italic>MGMT<\/jats:italic> promoters and generally are not sensitive to TMZ treatment. Detection of 2HG by MRS and molecular analysis, including non-canonical <jats:italic>IDH1\/2<\/jats:italic> mutations, were helpful in determining treatment response in this adult brainstem glioma case. Notably, hearing loss normalized after TMZ treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The diagnosis of IDH-mutant brainstem gliomas by MRS and integrated analysis of surgically obtained specimens is essential to determine the proper treatment of these rare cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1555986","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T05:28:27Z","timestamp":1751952507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Improved hearing in a rare, adult IDH2-mutant brainstem astrocytoma successfully treated with radiation and temozolomide"],"prefix":"10.3389","volume":"15","author":[{"given":"Takuya","family":"Okada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Natsumeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemoto","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayuta","family":"Higa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Tomikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoka","family":"Nishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arata","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihide","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Hanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyoshi","family":"Kakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0335","article-title":"Adult brainstem gliomas","volume":"17","author":"Reyes-Botero","year":"2012","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29920","article-title":"Adult brainstem gliomas","volume":"122","author":"Eisele","year":"2016","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not144","article-title":"H3F3A K27M mutations in thalamic gliomas from young adult patients","volume":"16","author":"Aihara","year":"2014","journal-title":"Neuro Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlae084","article-title":"Primary spinal cord gliomas: Pathologic features associated with prognosis","volume":"83","author":"Tanaka","year":"2024","journal-title":"J Neuropathol Exp Neurol"},{"key":"B8","volume-title":"World Health Organization classification of tumours of the central nervous system","author":"Louis","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1405-4","article-title":"Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers","volume":"129","author":"Korshunov","year":"2015","journal-title":"Acta Neuropathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40478-017-0500-2","article-title":"Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant","volume":"5","author":"Banan","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.ra.2018-0044","article-title":"MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas and MGMT silencing to temozolomide sensitivity in IDH-mutant gliomas","volume":"58","author":"Abe","year":"2018","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq205","article-title":"Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-04027-2","article-title":"The prognostic significance of HIST1H3B\/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age","volume":"158","author":"Vuong","year":"2022","journal-title":"J Neurooncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/neuonc\/noac198","article-title":"National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5414\/NP301085","article-title":"H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis","volume":"37","author":"Kleinschmidt-DeMasters","year":"2018","journal-title":"Clin Neuropathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"vdaa142","DOI":"10.1093\/noajnl\/vdaa142","article-title":"Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults","volume":"2","author":"Schulte","year":"2020","journal-title":"Neurooncol Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001897","article-title":"Diffuse midline gliomas with histone H3 K27M mutation in adults and children- A retrospective series of 164 cases","volume":"46","author":"Zheng","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1312-2","article-title":"Molecular analysis of diffuse intrinsic brainstem gliomas in adults","volume":"116","author":"Reyes-Botero","year":"2014","journal-title":"J Neurooncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2995","article-title":"Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3171\/2022.2.JNS211920","article-title":"Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients","volume":"137","author":"Wang","year":"2022","journal-title":"J Neurosurg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02194-y","article-title":"Infratentorial IDH-mutant astrocytoma is a distinct subtype","volume":"140","author":"Banan","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000003020","article-title":"Brainstem gliomas with isocitrate dehydrogenase mutation: natural history, clinical-radiological features, management strategy, and long-term outcome","volume":"95","author":"Pan","year":"2024","journal-title":"Neurosurgery"},{"key":"B23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40478-016-0351-2","article-title":"A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas","volume":"4","author":"Arita","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH 1 and IDH 2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.02134.x","article-title":"IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma","volume":"103","author":"SongTao","year":"2012","journal-title":"Cancer Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.2943","article-title":"A comparative study of short- and long-TE (1)H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors","volume":"26","author":"Choi","year":"2013","journal-title":"NMR BioMed"},{"key":"B27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","article-title":"Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials","volume":"21","author":"Vitanza","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12196","article-title":"Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas","volume":"35","author":"Ogura","year":"2015","journal-title":"Neuropathology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"155598","DOI":"10.1016\/j.prp.2024.155598","article-title":"All-in-one bimodal DNA and RNA next-generation sequencing panel for integrative diagnosis of glioma","volume":"263","author":"Higa","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2199895","article-title":"Administration of glucocorticoids prior to liquid biopsy dramatically reduces the detection rate of MYD88 L265P mutation in cerebrospinal fluid of primary CNS lymphoma patients","volume":"64","author":"Takahashi","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3171\/ped.2007.106.2.111","article-title":"Magnetic resonance imaging compared with biopsy in the diagnosis of brainstem diseases of childhood- a multicenter review","volume":"106","author":"Schumacher","year":"2007","journal-title":"J Neurosurg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2024.05.003","article-title":"Safety and efficacy of biopsy in patients with diffuse intrinsic pontine gliomas","volume":"187","author":"Chaturvedi","year":"2024","journal-title":"World Neurosurg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1478-0","article-title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","volume":"130","author":"Castel","year":"2015","journal-title":"Acta Neuropathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01568","article-title":"MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas","volume":"9","author":"Abe","year":"2019","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.08.024","article-title":"Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma","volume":"22","author":"Sturm","year":"2012","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e28228","DOI":"10.1002\/pbc.28228","article-title":"Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence","volume":"67","author":"Renzi","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s40478-014-0158-y","article-title":"Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy","volume":"2","author":"Natsumeda","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s10143-017-0908-y","article-title":"Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy","volume":"41","author":"Natsumeda","year":"2018","journal-title":"Neurosurg Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"116ra4","DOI":"10.1126\/scitranslmed.3002693","article-title":"Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy","volume":"4","author":"Andronesi","year":"2012","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat Med"},{"key":"B42","article-title":"Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma","volume":"18","author":"Nagashima","year":"2016","journal-title":"Neuro Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/diagnostics11112129","article-title":"Detection of 2-hydroxyglutarate by 3.0-tesla magnetic resonance spectroscopy in gliomas with rare IDH mutations: making sense of \u201cFalse-positive\u201d Cases","volume":"11","author":"Natsumeda","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3171\/2022.12.JNS221954","article-title":"2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma","volume":"139","author":"Iwahashi","year":"2023","journal-title":"J Neurosurg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1555986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T05:28:29Z","timestamp":1751952509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1555986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":44,"alternative-id":["10.3389\/fonc.2025.1555986"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1555986","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"article-number":"1555986"}}